Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no se ...